Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is approximately 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of $101 to a low of sixty one dolars.
In the newest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment includes selling of prescription drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as similar services, including medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in offering management as well as administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.